Each caplet of Neotibi contains 500 mg of pyrazinamide.
Pyrazinamide is bactericidal for M. tuberculosis hominis at an acidic pH. Clinically, pyrazinamide has been shown to be
especially effective against mycobacteria growing slowly in an acidic environment, eg caseous foci, pulmonary cavities.
In order to avoid inducing bacterial resistance, a risk inherent in all tuberculostatics when administered as monotherapy,
pyrazinamide should always be given together with other antituberculous agents, the standard core combination being,
pyrazinamide, isoniazid and rifampicin.
Pyrazinamide is one of the drugs used for the initial combined chemotherapy of pulmonary and extrapulmonary tuberculosis.
Patients hypersensitive to pyrazinamide.
Pyrazinamide should only be used when close observation of the patient is possible and when laboratory facilities are available
for performing liver function tests and blood uric determination every 2 – 4 weeks during therapy.
Special attention should be paid to patients with a history of hyperuricemia. Care should also be taken in patients with renal
SIDE EFFECTS :
Gastrointestinal Tract : nausea, anorexia, vomiting, diarrhoea and abdominal pain.
Liver : varying from occasional mild liver disorders to isolated cases of acute yellow atrophy of the
CNS : Mild fever and malaise may occur.
Urogenital System : Decreased renal excretion of uric acid, resulting in hyperuricaemia, may occur in dosage
exceeding 2 g / day.
The standard daily dosage for adults is 30 mg / kg body weight, given in a single daily dose. The total daily dose should not
exceed 3 g, irrespective of the patient’s body weight.
Keep in a cool and dry place.
Boxes of 10 x 10’s caplets. Reg. No : DKL 9021004204A1
ON DOCTOR’S PRESCRIPTION ONLY